510(k) device
Canvas Dx
Cognoa, Inc. · Pediatric Autism Spectrum Disorder Diagnosis Aid (QPF, Class II) · First FDA decision Apr 11, 2025, newest Apr 11, 2025
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
510(k) pathway
Device trials
1
Naming "Canvas Dx"
MAUDE reports
0
Brand "Canvas Dx", since 2015
PubMed studies
5
Mentioning "Canvas Dx"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Canvas Dx
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
- Canvas Dx510(k)
K243558 · Decided Apr 11, 2025 · 144 days after receipt
Device type: Pediatric Autism Spectrum Disorder Diagnosis Aid (QPF) · Neurology & Neurosurgery
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Canvas Dx", any status and sponsor, newest update first.
- Extension for Community Healthcare Outcomes (ECHO) Autism Diagnostic Study in Primary Care SettingCompleted
Cognoa, Inc.Not on our public-company list
NCT05223374 · 110 participants · Start Mar 1, 2022 · Primary completion Feb 4, 2024
Device: Canvas Dx · For: Children18-72 Months With a Suspicion Autistic Disorder
Sites: Columbia, Missouri
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Canvas Dx", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code QPF
0 reports: 0 malfunction, 0 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Canvas Dx"[tiab]. The summary above synthesizes these.
- An analysis of the real world performance of an artificial intelligence based autism diagnostic.
Salomon C, Heinz K, Aronson-Ramos J, et al. · Sci Rep · 2025
- Integration of an Artificial Intelligence-Based Autism Diagnostic Device into the ECHO Autism Primary Care Workflow: Prospective Observational Study.
Sohl K, Linstead E, Heinz K, et al. · JMIR Form Res · 2025Observational Study, Research Support, Non-U.S. Gov't
- Integration of an FDA-Authorized Digital Autism Diagnostic Tool Into an Outpatient Developmental Pediatrics Workflow: Preliminary Quality Improvement Study.
Resnik JB, Lane RT, Turnacioglu SO · JMIR Form Res · 2026
- [Artificial intelligence in child and adolescent psychiatry: A critical review of uses, evidence and relational stakes].
Bonnot O, Mouhoud T, Shadili G, et al. · Encephale · 2026English Abstract
- Artificial-intelligence-based developmental screening for pre-school children (ages 3-6): a scoping review of deployed tools, clinical validity, equity, and implementation in guidance-center settings.
Arslan A, Gül F · Front Psychol · 2026Review
Other devices of this type
Also filed under product code QPF.
- EarliPoint SystemEarlitec Diagnostics · 510(k) 2025
- NeuroraArgus Cognitive, Inc. · 510(k) 2026
- EarliPoint AssessmentEarlitec Diagnostics · 510(k) 2026
- Cognoa ASD Diagnosis AidCognoa, Inc. · De Novo 2021
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.